EndoTODAY | EndoATLAS | Outpatient Clinic
Parasite | Esophagus | Stomach | Cancer | ESD
Home | Guide | Author | Subscription | Links
[Á¦55ȸ ´ëÇѼÒȱ⳻½Ã°æÇÐȸ ¼¼¹Ì³ª]
ÀϽÃ: 2016³â 8¿ù 28ÀÏ
Àå¼Ò: ÀÏ»ê ŲÅýº
1. ÁúÇâ»ó ºÐ¾ßÀÇ »õ·Î¿î ±âȸ ¼±µµÇϱâ (Room E. 9:00-10:30)
1) Çѱ¹ÀÇ ÀÇ·á Áú ÇöȲ°ú °³¼± ¹æÇâ (¼º±Õ°ü´ëÇб³ ÀÌÁØÇà)
OECD¿¡¼ Æò°¡ÇÑ ¿ì¸®³ª¶ó ÀÇ·áÀÇ ÁúÀû ¼öÁØÀº ºñ±³Àû ³ôÀº ÆíÀÌÁö¸¸, ±¹³» ÀÇ·áÁøÀ̳ª ±¹¹ÎµéÀÌ ´À³¢´Â ¿ì¸®³ª¶ó ÀÇ·áÀÇ ¼öÁØÀº ±×´ÙÁö ³ôÁö ¾Ê½À´Ï´Ù. Àú¼ö°¡ ±¸Á¶¿Í ÀÇ·áÀü´Þü°è ºØ±«¿¡ µû¸¥ ÇüÆí¾ø´Â ¼ºñ½º ¶§¹®À¸·Î »ý°¢µË´Ï´Ù. ±×°£ ¿©·¯ºÐµéÀÇ ³ë·ÂÀ» ÅëÇÏ¿© µ·µéÀÌÁö ¾Ê°í ÇÒ ¼ö ÀÖ´Â ÀÏÀº ´ë° ÁøÇàµÇ¾ú½À´Ï´Ù. º¸´Ù ³ôÀº ¼öÁØÀÇ ÁúÇâ»óÀ» À§Çؼ´Â ¹«¾ùº¸´Ù Àç¿øÀÌ ÅõÀڵǾî¾ß ÇÕ´Ï´Ù. ÃæºÐÇÑ ³»½Ã°æ ¼Òµ¶À» À§Çؼ´Â ³»½Ã°æ ¼Òµ¶ ¼ö°¡°¡ ÀûÀýÇÏ°Ô ¼³Á¤µÇ¾î¾ß ÇÏ´Â °Íó·³ ¸»ÀÔ´Ï´Ù... û³âÀÇ»ç Ä«µå ´º½º ÀϺθ¦ ¿Å±é´Ï´Ù.
* Âü°í: EndoTODAY ȯÀÚ ¾ÈÀü
2016³â 8¿ù 28ÀÏ ³»½Ã°æ¼¼¹Ì³ª¿¡¼ ÀÖ¾ú´ø °ÀÇ(Çѱ¹ÀÇ ÀÇ·á Áú ÇöȲ°ú °³¼± ¹æÇâ)¿¡ Âü¿©ÇϽŠÇÑÁ¤È£ ±³¼ö´Ô²²¼ °á·Ð ½½¶óÀÌµå »çÁø¿¡ ÀÇ°ßÀ» ºÙ¿© Facebook¿¡ ¿Ã·ÁÁּ̽À´Ï´Ù. °¨»çÇÕ´Ï´Ù.
2) ÀÌ»óÀûÀÎ ³»½Ã°æ½Ç ¼ÂÆà (°í·Á´ëÇб³ ±èÀº¼±)
±èÀº¼± ±³¼ö´ÔÀº ³»½Ã°æ½Ç¿¡¼ 'ȯÀÚÀÇ flow'¸¦ °Á¶Çϼ̽À´Ï´Ù. (1) ´ë±â½Ç¿¡¼ °Ë»ç½Ç±îÁö À̵¿ °Å¸® ÃÖ¼ÒÈ, (2) °Ë»ç ÈÄ È¸º¹½ÇÀ̳ª Å»ÀÇ½Ç À̵¿ÀÌ ÆíÇϵµ·Ï, (3) ¿À¿°µÈ ±â±âÀÇ µ¿¼±°ú Á÷¿øÀÇ µ¿¼±À» ±¸ºÐ, (4) ÀÔ¿ø ȯÀÚ / ¿Ü·¡ ȯÀÚ / °æÁõ ȯÀÚ / ÁßÁõ ȯÀÚ µ¿¼±À» ±¸ºÐ
¹Ì±¹ ÀÚ·áÁö¸¸ À§³»½Ã°æ¿¡ 0.7 ½Ã°£ÀÌ ¼Ò¿äµÇ°í ´ëÀå³»½Ã°æ¿¡ 1.5 ½Ã°£ÀÌ ¼Ò¿äµÇ´Â °ÍÀ¸·Î ÇÊ¿äÀηÂÀ» °è»êÇÑ´Ù°í ÇÕ´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼´Â À§³»½Ã°æ 10ºÐ, ´ëÀå³»½Ã°æ 20ºÐ Á¤µµ °è»êÇÕ´Ï´Ù.
[ÀÌÁØÇà comment] ÃÖ±Ù openÇÑ Ã¢¿øÁö¿ªÀÇ ÇÑ ±¹¸³´ë º´¿ø ³»½Ã°æ½ÇÀ» ¹æ¹®ÇÑ ¹Ù ÀÖ½À´Ï´Ù. ±ô¦ ³î¶ú½À´Ï´Ù. ¿¹»óº¸´Ù °Ë»ç½ÇÀ̳ª ȸº¹½ÇÀÌ ÈξÀ ³Ð¾ú°í, ȯÀÚ flow°¡ ÀÚ¿¬½º·´°Ô ¼³°èµÇ¾î ÀÖ¾úÀ¸¸ç, live demonstration ¼³ºñ°¡ °®ÃçÁ® ÀÖ¾ú°í, ¹Ì·¡¸¦ ´ëºñÇÑ È®À强µµ ÃæºÐÇÏ¿´½À´Ï´Ù. ¹«¾ùº¸´Ùµµ 1Ãþ ÀÀ±Þ½Ç¿¡¼ 2Ãþ ³»½Ã°æ½Ç·Î Á÷Á¢ ¿¬°áµÇ´Â ȯÀÚÀÌ¼Û Àü¿ë ¿¤¸®º£ÀÌÅÍ°¡ ÀÖ¾ú½À´Ï´Ù. ¾î¶»°Ô ÀÌ·± ÈǸ¢ÇÑ ½Ã¼³À» °®Ãß°Ô µÇ¾ú´ÂÁö Áú¹®ÇÏ¿´½À´Ï´Ù. (³»½Ã°æ Àü¹®) ¼Òȱ⳻°ú ±³¼ö²²¼ º´¿ø ¼³°è ´Ü°èºÎÅÍ Àû±ØÀûÀ¸·Î ÀÇ°ßÀ» ³»¼Ì´Ù°í ÇÕ´Ï´Ù. ÈǸ¢ÇÑ ³»½Ã°æ½ÇÀº ÀúÀý·Î ¶³¾îÁö´Â °ÍÀº ¾Æ´Ï¶ó°í »ý°¢ÇÕ´Ï´Ù. Æò¼ÒºÎÅÍ Æ¯È÷ renovation ½ÃÁ¡¿¡¼ ³»½Ã°æ½Ç ÀÇ»çµéÀÌ Àû±ØÀûÀ¸·Î Âü¿©ÇÏ°í Áú ÁÁÀº ³»½Ã°æ½ÇÀÌ ÇÊ¿äÇÏ´Ù´Â Á¡À» ÀûÀýÈ÷ ÁÖÀåÇÏ°í °üö½ÃÄÑ¾ß ÇÕ´Ï´Ù. ³»½Ã°æ ÀÇ»çÀÇ Á¤Ä¡·ÂÀÌ ¸Å¿ì Áß¿äÇÏ´Ù´Â Á¡À» ¸»¾¸µå¸®°í ½Í½À´Ï´Ù.
3) ÀÇ·á±â°üÆò°¡ ÀÎÁõÀ» À§ÇÑ ³»½Ã°æ½Ç Áغñ (ÇѾç´ëÇб³ ÀÌ°³ç)
"ÇöÀç ÀÎÁõÁ¦ÀÇ Æò°¡³»¿ëÀº 4°³ ¿µ¿ª, 13°³ Àå, 48°³ ¹üÁÖ, 91°³ ±âÁØ, 537°³ Á¶»çÇ׸ñÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù... ³»½Ã°æ °Ë»ç¸¦ À§ÇØ ÁøÁ¤Á¦¸¦ Åõ¿©¹ÞÀº ȯÀÚ´Â ³«»óÀÇ °íÀ§Ç豺ÀÓÀ» °¨¾ÈÇÏ¿© ¹Ýµå½Ã º¸È£ÀÚ¸¦ µ¿¹ÝÇϵµ·Ï ÇÑ´Ù. °Ë»ç Àü¿¡ ÈÀå½Ç¿¡ ´Ù³à¿Àµµ·Ï Çϸç, ³ôÀº ±ÁÀº ½ÅÁö ¾Êµµ·Ï ÇÏ°í, ÈÙü¾î ¹ÙÄû´Â °íÁ¤ÇÏ°í, ħ»ó ³°£Àº ¿Ã¸°´Ù. ¹Ù´ÚÀº ¹Ì²ô·´Áö ¾Ê°Ô ÇÏ°í ÀûÀýÇÏ Á¶¸í°ú ³«»ó¿¹¹æ °Ô½Ã¹°À» °®Ãá´Ù."
2. »óºÎÀ§Àå°ü ÀÀ±Þ³»½Ã°æ (A room)
1) ½Äµµ À̹° Á¦°Å (ÇѸ²´ëÇб³ ¹é±¤È£)
PTP¸¦ ±×´ë·Î »ïÄÑ ÀÀ±Þ½Ç·Î ¿À½Ã´Â ȯÀÚ°¡ ÀÖ½À´Ï´Ù. ³»½Ã°æÀ¸·Î PTP¸¦ Á¦°ÅÇÒ ¶§¿¡´Â ½Äµµº® ¼Õ»ó¿¡ ÁÖÀÇÇØ¾ß ÇÕ´Ï´Ù. CapÀ» »ç¿ëÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù.
±³¼ö´ÔÀº "µ¿Àü°ú °°ÀÌ ÀúÀý·Î ¹èÃâµÉ °¡´É¼ºÀÌ ³ôÀº À̹° ¶Ç´Â Æó¼â Á¤µµ°¡ ³·Àº °æ¿ì Áõ»óÀÌ ¾ø´Ù¸é 24½Ã°£±îÁö °æ°ú °üÂû °¡´É"ÇÏ´Ù´Â ¸»¾¸À¸·Î °ÀǸ¦ ¸¶Ä¡¼Ì½À´Ï´Ù. »¡¸®ÇÏ´Â °Íµµ Áß¿äÇÏÁö¸¸ ¾ÈÀüÇÏ°í Á¤È®ÇÏ°Ô ½Ã¼úÇÏ´Â °ÍÀÌ ´õ Áß¿äÇÏ´Ù´Â ¸»¾¸À̶ó°í »ý°¢µË´Ï´Ù. ¹é±¤È£ ±³¼ö´Ô²²¼´Â ¸Å¿ì ¸¹Àº Èï¹Ì·Î¿î Áõ·Ê¸¦ º¸¿©Áּ̽À´Ï´Ù. EndoTODAY¿¡ ¸ðµÎ ¼Ò°³Çϱ⠾î·Æ½À´Ï´Ù. ÇâÈÄ ÇÐȸ ȨÆäÀÌÁö¸¦ ÅëÇÏ¿© µ¿¿µ»ó °ÀǸ¦ µé¾îº¸½Ç °ÍÀ» ±ÇÇÕ´Ï´Ù.
2) ÃâÇ÷¼º ±Ë¾ç ³»½Ã°æ Ä¡·á (°¡Å縯´ëÇб³ ±èº´¿í)
"ÀϹÝÀûÀ¸·Î 24½Ã°£ À̳» ³»½Ã°æÀû ÁöÇ÷¼úÀ» ½ÃÇàÇÒ °æ¿ì »ç¸Á·ü, ÀçÃâÇ÷·ü µî¿¡´Â Å©°Ô Â÷ÀÌ°¡ ¾ø´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ´ëºÎºÐÀÇ Áø·á ÁöħÀº 24½Ã°£ À̳»¿¡ ³»½Ã°æÀû ÁöÇ÷¼úÀ» ½ÃÇàÇÒ °ÍÀ» ±Ç°íÇÏ°í ÀÖ´Ù. 2-6½Ã°£ À̳», ¶Ç´Â 12½Ã°£ À̳» ³»½Ã°æ °Ë»ç¸¦ ½ÃÇàÇÏ´Â °ÍÀº ÀÓ»óÀû °á°ú¸¦ ÁÁ°Ô ÇÒ ¼ö ÀÖ´Ù´Â º¸°íµµ ÀÖÁö¸¸, Ç÷¿ªÇÐÀûÀ¸·Î ¾ÈÁ¤µÈ ȯÀÚ¿¡¼ 12½Ã°£ À̳» ³»½Ã°æÀ» ½ÃÇàÇÏ´Â °æ¿ì ºÒÇÊ¿äÇÑ ÁöÇ÷¼ú µîÀ» ½ÃÇàÇÒ °¡´É¼ºÀÌ ³ô´Ù´Â ÁÖÀåµµ ÀÖ´Ù."
"°á·Ð: ¾ç¼ºÀÚÆßÇÁ¾ïÁ¦Á¦¸¦ »ç¿ëÇÏ´Â Áö±ÝÀº ¼Òȼº±Ë¾ç ÃâÇ÷À» Æ÷ÇÔÇÑ Á¤¸Æ·ù ÃâÇ÷ÀÌ ¾Æ´Ñ »óºÎÀ§Àå°ü ÃâÇ÷ÀÇ ÀûÀýÇÑ Ä¡·á ½Ã±â´Â 24½Ã°£ À̳»·Î »ý°¢µÈ´Ù."
* Âü°í: EndoTODAY ¼Òȼº±Ë¾ç ÃâÇ÷
3) Ç×Ç÷¼ÒÆÇÁ¦¿Í NOAC º¹¿ë ȯÀÚÀÇ ÀÀ±Þ³»½Ã°æ (ÇѸ²´ëÇб³ ½Å¿î°Ç)
2015³â 7¿ùºÎÅÍ NOACÀÇ ½ÉÆò¿ø ÀûÀÀÁõÀÌ È®´ëµÇ¾ú±â ¶§¹®¿¡ »ç¿ëȯÀÚ°¡ ±ÞÁõÇÏ¿´½À´Ï´Ù.
Dabigatran reversal agent (idarucizumab, Praxbind)°¡ FDA °øÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.
±èÀç±Ô ÁÂÀå´Ô Áú¹®: ½Å¿î°Ç ±³¼ö´ÔÀº ½ÇÁ¦·Î ¾î¶»°Ô ÇÏ°í °è½Ê´Ï±î?
→ ½Å¿î°Ç ±³¼ö´Ô ´äº¯: ¾Æ½ºÇǸ°°ú Ŭ·ÎÇǵµ±×·¼Àº ²÷µµ·Ï ±ÇÇÏÁö ¾Ê½À´Ï´Ù. ¿ÍÆĸ° º¹¿ëÇϴ ȯÀÚ´Â PT¸¦ È®ÀÎÇÑ ÈÄ 5ÀÏ Á¤µµ ²÷µµ·Ï ÇÏ°í ÀÖ½À´Ï´Ù.±èÀç±Ô ÁÂÀå´Ô Áú¹®: ȯÀÚ°¡ ´Ù¸¥ ÀÇ·á±â°ü¿¡¼ Ä¡·áÇÏ°í ÀÖ°í ¾î¶² ¾àÀ» ¸Ô°í ÀÖ´ÂÁö ¸ð¸£°í ÀÖÀ¸¸é ¾î¶»°Ô ÇϽʴϱî?
→ ½Å¿î°Ç ±³¼ö´Ô ´äº¯: ±ÞÇÑ °æ¿ì°¡ ¾Æ´Ï¸é Àû¾îµµ ó¹æÀü Á¤µµ´Â È®ÀÎÇÏ°í ÀÖ½À´Ï´Ù.ûÁß Áú¹®: Stent »ðÀÔ 1³â À̳»¿¡ EGC Áø´ÜÀ» ¹Þ¾Æ¼ ESD¸¦ ÇÏ·Á´Âµ¥ clopidogrelÀº ²÷°í aspirinÀº ¾²¸é¼ ESD¸¦ Çß½À´Ï´Ù. ´ç½Ã ÃâÇ÷ÀÌ ¸¹¾Ò´Âµ¥¿ä, ±³¼ö´ÔÀº ¾î¶»°Ô ÇϽô°¡¿ä?
→ ½Å¿î°Ç ±³¼ö´Ô ´äº¯: Cardiologist°¡ °áÁ¤À» ÇØ ÁÖ¸é aspirin¸¸ ¾²¸é¼ ESD¸¦ ÇÏ°í ÀÖ½À´Ï´Ù. ¾Æ½ºÇǸ°À» ¾²¸é¼ ½Ã¼úÀ» ÇÏ¸é ½Ã¼ú ´ç½Ã ÃâÇ÷ÀÌ Á¶±Ý ¸¹±â´Â ÇÏÁö¸¸, Áö¿¬ ÃâÇ÷Àº Å©°Ô ´Ù¸£Áö ¾Ê¾Ò´ø °Í °°½À´Ï´Ù.* Âü°í: EndoTODAY ³»½Ã°æ ȤÀº Á¶Á÷°Ë»ç Àü ¾Æ½ºÇǸ°, Ç×Ç÷¼ÒÆÇÁ¦¸¦ ²÷À» °ÍÀΰ¡?
* Âü°í: EndoTODAY NOAC (new oral anticoagulant) »õ·Î¿î Ç×ÀÀ°íÁ¦
4) ESD ÈÄ ÃâÇ÷ÀÇ ¿¹¹æ°ú ³»½Ã°æ Ä¡·á (µ¿¾Æ´ëÇб³ ÀåÁø¼®)
The only significant risk factor for delayed bleeding was the occurrence of immediate bleeding. The delayed bleeding may be caused by insufficient coagulation during resection, but not by insufficient initial hemostasis. (Matsushita et al. Scand J Gastroenterol 2010).
ÃÖ±Ù ¿¬±¸¿¡¼µµ ESD Àü ¾Æ½ºÇǸ°À» °è¼Ó »ç¿ëÇÏ´Â °ÍÀº ÃâÇ÷À§ÇèÀÎÀÚ°¡ ¾Æ´Ï¶ó´Â °á°ú¿´½À´Ï´Ù. Èï¹Ì·Î¿î Á¡Àº heparinÀ» »ç¿ëÇÏ´Â °ÍÀº ÃâÇ÷ À§ÇèÀ» ³ô¿´´Ù´Â Á¡ÀÔ´Ï´Ù (WJGE 2016 April 10).
Continued administration of antiplatelet agents, based on the guidelines, was not a risk factor for postoperative bleeding after ESD; however, heparin replacement, which is recommended after withdrawal of oral anticoagulants, was identified as a significant risk factor.
Fibrin glue, self-assembling matrix forming gel, polyglycolic acid felt µîÀ» Ãß°¡Çϸé ÃâÇ÷À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ´Ù´Â º¸°í°¡ ÀÖ½À´Ï´Ù. ÇâÈÄ Ãß°¡ ¿¬±¸°¡ ÇÊ¿äÇÕ´Ï´Ù.
[ÀÌÁØÇà comment] °ú°Å¿¡´Â °£È¤ aspirinÀ» ²÷°í °ÆÁ¤µÈ´Ù¸é¼ heparinÀ» »ç¿ëÇÏ´Â ¼±»ý´ÔÀÌ °è¼Ì½À´Ï´Ù. »ç½Ç ÀüÇô ÇÊ¿ä¾ø´Â ÀÏÀÔ´Ï´Ù. AspirinÀ» »ç¿ëÇÏ´Â °æ¿ì¿Í heparinÀ» »ç¿ëÇÏ´Â °æ¿ì°¡ ÀüÇô ´Ù¸£±â ¶§¹®ÀÔ´Ï´Ù. ±×¸®°í heparinÀº ÃâÇ÷ À§ÇèÀ» Áõ°¡½Ãŵ´Ï´Ù. ÇÊ¿äÇÏÁöµµ ¾Ê°í À§ÇèÇÒ »ÓÀÎ ÀÏÀº ÇÏÁö ¾Ê´Â °ÍÀÌ »óÃ¥ÀÔ´Ï´Ù.
3. À§ ESD ¹è¿ì±â (D room, 13:20-14:50)
1) ESD knifeÀÇ Æ¯¼º ¹× ÃÖÀûÀÇ electrosurgical unit ¼³Á¤ (Ãæ³²´ëÇб³ ¹®Èñ¼®)
ESD¸¦ °³¹ßÇÑ ÀϺ» µ¿°æ¾Ï¼¾ÅÍÀÇ ±â¼úÀû ¾ÈÁ¤È °úÁ¤ÀÔ´Ï´Ù. Delayed bleeding°ú en bloc resectionÀÇ ¾ÈÁ¤È¿¡´Â 4-5³âÀÌ °É·È½À´Ï´Ù. ±×·¯³ª intraoperative bleeding ¾ÈÁ¤È¿¡´Â Á» ´õ ¸¹Àº ½Ã°£ÀÌ ÇÊ¿äÇß½À´Ï´Ù.
¾ÆÁ÷ market share´Â ÀûÁö¸¸ ¿ì¸®³ª¶ó¿¡¼µµ ¿©·¯ Àý°³µµ°¡ °³¹ßµÇ¾ú½À´Ï´Ù. ÃÖ±Ù¿¡ ¹ß¸ÅµÈ °ÍÀº Optimos ESD knife ÀÔ´Ï´Ù (Clin Endosc 2014;47:544).
[ÀÌÁØÇà comment] ¿ì¸®³ª¶ó¿¡¼´Â ESD ½Ã Ưº°ÇÑ ÀÌÀ¯°¡ ¾øÀ¸¸é ÇÑ °³ÀÇ Àý°³µµ¸¸ û±¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÏȸ¿ë (single use only) µµ±¸´Â Àç¼Òµ¶ÇÏ¿© »ç¿ëÇÒ ¼ö ¾ø½À´Ï´Ù (Âü°í ÀÚ·á). ESD initial precutting¿¡¼´Â Dual knife¸¦ »ç¿ëÇÏ°í ±âŸ ½Ã¼úÀº IT-2 knife¸¦ »ç¿ëÇÏ¸é »ó´çÈ÷ °ï¶õÇÑ »óȲ¿¡ ºüÁý´Ï´Ù. û±¸ÇÒ ¹æ¹ýÀÌ ¾ø±â ¶§¹®ÀÔ´Ï´Ù. ¾î¿ ¼ö ¾øÀÌ initial precuttingÀº ¾à°£ÀÇ À§ÇèÀ» °¨¼öÇÏ°í reusable needle knife¸¦ ÀÌ¿ëÇϱ⵵ ÇÕ´Ï´Ù. ÇâÈÄ ¸ðµç ½Ã¼úÀ» ÇÒ ¼ö ÀÖ´Â ´Ù±â´É Àý°³µµ°¡ ¸¹ÀÌ »ç¿ëµÉ °Í °°½À´Ï´Ù. ÃÖ±Ù¿¡ Àú´Â ¸ðµç ½Ã¼úÀ» Dual knife·Î ÇÏ°í ÀÖ½À´Ï´Ù. IT-2 knife¸¦ »ç¿ëÇÏÁö ¾ÊÀ» ¼ö ¾ø´Â °æ¿ì¿¡´Â ³»½Ã°æ °á°úÁö¿¡ ±× ÀÌÀ¯¸¦ ±â·ÏÇÑ ÈÄ Dual knife¿Í IT-2 knife¸¦ ¸ðµÎ û±¸ÇÏ°í ÀÖ½À´Ï´Ù. ¾Æ¸¶µµ ¸¹Àº ¼ö°¡ »è°¨µÉ °Í °°½À´Ï´Ù.
* Âü°í: EndoTODAY °íÁÖÆĹ߻ýÀåÄ¡
2) ÃʽÉÀÚ¸¦ À§ÇÑ ESD ÀûÀÀÁõ ¼±Á¤ °¡À̵å (°í·Á´ëÇб³ ¹ÚÁ¾Àç)
ÃâÇ÷À» ÁÙÀ̱â À§ÇÑ ¹ÚÁ¾Àç ±³¼ö´ÔÀÇ tip: Slow movement of knife with increasing coagulation time by increasing cutting interval when using EndoCut mode. Rapid movement of knife using coagulation mode only rather than cutting or EndoCut mode.
3) À§ ESD ¹è¿ì±â - ³ªÀÇ ÁÂÃæ¿ìµ¹ (Á¦ÁÖ´ëÇб³ ³ª¼ö¿µ)
ȯÀÚ ¾ÈÀüÀÌ Áß¿äÇϹǷΠȥÀÚ ½ÃÀÛÇÏÁö ¸»°í Àü¹®°¡ ÁöµµÇÏ °æÇèÀÌ Áß¿äÇÏ´Ù´Â Á¡À» °Á¶Çϼ̽À´Ï´Ù.
±Ã±ÝÇÑ Á¡ÀÌ ÀÖÀ» ¶§¸¶´Ù »ó´ãÇÒ ¼ö ÀÖ´Â mentor¸¦ °¡Áø´Ù´Â °ÍÀº Á¤¸»·Î Áß¿äÇÑ ÀÏÀÔ´Ï´Ù.
³ª¼ö¿µ ±³¼ö´ÔÀÇ ³»½Ã°æ½Ç setting (Á¦ÁÖ´ëÇб³º´¿ø)
³»½Ã°æ¸¶´Ù Ư¡ÀÌ ´Ù¸¨´Ï´Ù. ÃÖ±ÙÀÇ ³»½Ã°æÀº ³Ê¹« º¹ÀâÇÏ¿© Á¶ÀÛ¼ºÀÌ ¶³¾îÁö´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. H scopeº¸´Ù Q scope°¡ ´õ flexible ÇÕ´Ï´Ù.
óÀ½¿¡´Â ¾î·Á¿ü´ø pyloric ring º´¼Ò¸¦ ³ªÁß¿¡´Â ¼º°øÀûÀ¸·Î ½Ã¼úÇÒ ¼ö ÀÖ¾ú´Ù°í ÇÕ´Ï´Ù. ÃàÇÏÇÕ´Ï´Ù.
ESD ½Ã¼ú ½Ã°£µµ Á¡Â÷ ª¾ÆÁø´Ù´Â °ÍÀ» ÀÚ½ÅÀÇ µ¥ÀÌŸ·Î º¸¿©Áּ̽À´Ï´Ù. óÀ½¿¡´Â ½¬¿î º´¼Ò¿¡¼ ½ÃÀÛÇÏ¿© Á¡Â÷ ¾î·Á¿î º´¼Ò·Î ³Ñ¾î°¬À» °ÍÀÓ¿¡µµ ºÒ±¸ÇÏ°í Æò±Õ ½Ã°£Àº 40ºÐ ÀüÈÄ·Î À¯ÁöµÇ°í ÀÖ½À´Ï´Ù. 90°³ ÀÌ»óºÎÅÍ´Â ½Ã¼ú ½Ã°£ÀÌ 100ºÐÀ» ³Ñ´Â °æ¿ì°¡ ¾ø¾ú½À´Ï´Ù.
³ª¼ö¿µ ±³¼ö´ÔÀº ESD ½Ã¼ú ¿¹°¡ 200°³ Á¤µµÀÔ´Ï´Ù. ÇÏÁö¸¸ ¾ÆÁ÷µµ ´ÙÀ½ ³¯ ¾î·Á¿î ESD ½Ã¼úÀÌ ÀâÇôÀÖ´Â °æ¿ì¿¡´Â Ã¥°ú DVD¸¦ º¸¸é¼ '³»ÀÏ ¾î¶»°Ô ½Ã¼úÇÒÁö image trainingÀ» ÇÑ´Ù'°í ¸»¾¸Çϼ̽À´Ï´Ù.
Ãʺ¸ÀÚ¿¡°Ô °¡Àå Áß¿äÇÑ °Í µÎ °¡Áö´Â '(1) °â¼ÕÇÑ ¸¶À½°ú (2) ÀûÀýÇÑ È¯ÀÚ ¼±ÅÃ'À̶ó°í °Á¶Çϼ̽À´Ï´Ù.
"³ªÇÑÅ×´Â ¿Ö ÃâÇ÷ÀÌ ½ÉÇÑ È¯ÀÚ¸¸"À̶ó°í °í¹ÎÀ» Çߴµ¥ ±× ¿øÀÎÀÌ ¾èÀº Àý°³¿´½À´Ï´Ù. ÃæºÐÇÑ Àý°³¸¦ ÇÏÁö ¾ÊÀ¸¸é Á¡¸·ÇÏ ¹Ú¸®°¡ ¾î·Á¿ö ÃâÇ÷ÀÌ ¸¹´Ù´Â °ÍÀ» µÚ´Ê°Ô ¾Æ¼Ì´Ù°í ÇÕ´Ï´Ù.
4) Áøº¸µÈ ¼ú±â ¹× Àü¹®°¡·Î °¡´Â ±æ (¿ï»ê´ëÇб³ Á¤ÈÆ¿ë)
"Ä¡·á³»½Ã°æÀº ¼ÕÀ¸·Î ½Ã¼úÇÏ´Â °ÍÀΰ¡? ȤÀº ¸Ó¸®·Î ½Ã¼úÇÏ´Â °ÍÀΰ¡? ¾Æ¸¶µµ ¼÷ÁöÇÑ Áö½Ä°ú Àü·«À» ¸Ó¸®·Î ÃæºÐÈ÷ Á¤¸®ÇÑ ÈÄ ½Ã¼úÀ» ÇÏ´Â °ÍÀ̶ó°í »ý°¢ÇÑ´Ù. ´Ù½Ã ¸»Çؼ, ¼Õ±â¼ú¸¸À¸·Î Ä¡·á¿¡ ÀÓÇÏ´Â °ú¿À´Â ¹üÇÏÁö ¸»¾Æ¾ß ÇÑ´Ù. Ä¡·á³»½Ã°æ ½Ã¼úÀÌ °¡´ÉÇÏ´Ù°í ÆÇ´ÜÇßÀ» ¶§, ¹Ù·Î ´ýºñÁö ¸»°í Çѹߦ ¹°·¯³ª¼ ´«¿¡ º¸ÀÌ´Â À̵æ°ú ÀáÀçÀûÀÎ ¼ÕÇظ¦ ÇÔ²² °¨¾ÈÇÏ¿© Ä¡·á °áÁ¤À» Çϵµ·Ï ÇÑ´Ù. ±×·¡¾ß¸¸ ¹«¸®ÇÑ Ä¡·á ½Ã¼úÀ» ¹æÁöÇÒ ¼ö ÀÖ´Ù. ÀûÀýÇÑ °áÁ¤(optimal decision making)À» Çϱ⸦ ±â´ëÇÑ´Ù. Ä¡·áÀÇ È¿°ú¸¸ °Á¶ÇÏ¿© Ä¡·á¸¦ ±ÇÀ¯ÇÑ´Ù¸é ¹«¸®ÇÑ Ä¡·á¹ýÀÌ µÉ ¼ö ÀÖÀ» °ÍÀ̸ç, ºÎÀÛ¿ë°ú ÇÕº´ÁõÀ» ³Ê¹« °Á¶ÇÏ¸é ºÒ¾È°¨À» Á¶¼ºÇÏ´Â ¿ì¸¦ ¹üÇÏ°Ô µÈ´Ù. ´Ù½Ã Çѹø °Á¶ÇÏÁö¸¸, optimal decision making¿¡ ¸¹Àº ½Ã°£À» ÅõÀÚÇÏ°í, ¿¸° ¸¶À½À¸·Î ȯÀÚ¿Í Ä¡·á¿¡ ´ëÇØ »óÀÇÇϱ⸦ ±ÇÀ¯ÇÑ´Ù."
ESD ÀÔ¹®À» À§Çؼ´Â 5 °¡Áö°¡ ÇÊ¿äÇÕ´Ï´Ù.
- Knowledge: (1) Techinical knowledge, (2) Indication, (3) Personal ability
- Strategy:
- Techniques
- Complications
- Feedback
¼ÕÀº ´ëºÎºÐ ¿¬¸¶ÇÒ ¼ö ÀÖÁö¸¸, ¸Ó¸®´Â ½±Áö ¾Ê´Ù.
°ÀÇ Áß º¸¿©ÁֽŠsubmucosal tumorectomy Áõ·Ê. õ°øÀÌ ÀÖ¾î clippingÀ» ÇÏ¿´À½.
* ÂüÁ¶: EndoTODAY ³»½Ã°æÁ¡¸·ÇÏÀýÁ¦¼ú (ESD)
1) ³»½Ã°æÇÐȸ ÇмúÇà»ç on-line Áß°è
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.